Journal of Hematology Oncology Pharmacy

Featured Articles

Editorial

Protecting Patients with Cancer During the COVID-19 Pandemic

Robert Mancini, PharmD, BCOP, FHOPA, Timothy G. Tyler, PharmD, FCSHP, FHOPA

Original Article

Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent

Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP

Original Article

Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies

Christopher Sinoimeri, PharmD, Bryan Do, PharmD, BCOP, Sheree Chen, PharmD, BCOP

Original Article

Impact of Letermovir for Cytomegalovirus Prophylaxis in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Brianna Archambeau, PharmD, BCOP, Ashley M. Leece, PharmD, BCOP, BCPS, Dhaval Patel, PharmD, BCOP, Chin Y. Liu, MS, PharmD, BCOP

Case Reports

Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series

Review Article

Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer

Seon Jo Park, PharmD, BCOP, Benjamin Yoder, PharmD, Tammy Li, PharmD

From the Literature

First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature

Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature

Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

FDA Oncology Update

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Meeting Highlights

Immune Responses to COVID-19 Vaccines Low Among Patients with Hematologic Malignancies, but mRNA Vaccines Induce Strong Antibody Response in AML and MDS

A Paradigm Shift: CAR T-Cell Therapy Beats Standard of Care as Second-Line Treatment for Large B-Cell Lymphoma

Polatuzumab Vedotin plus R-CHP Outperforms R-CHOP as First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma

Ivosidenib Added to First-Line Azacitidine Improves Outcomes in Older Patients with AML

Mosunetuzumab, a Bispecific Antibody, Induces Deep Remissions in Relapsed or Refractory Follicular Lymphoma

Isatuximab plus RVd Regimen Achieves Highest Rates of No MRD in Patients with Multiple Myeloma

Time-Limited Venetoclax Combinations Superior to Chemoimmunotherapy in Fit Patients with CLL

Using Value-Based Contracts to Manage Oncology Costs While Keeping Focus on the Patient

The Impact of Telehealth on Cancer Care

Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.